Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

The aim of this prospective open trial was to evaluate the efficacy in normalizing IGF-I levels of the addition of cabergoline to the treatment of acromegalic patients partially responsive to Octreotide-LAR (OCT-LAR), a long acting somatotastin analog (SSA). Fifty-two patients who did not achieve ho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pituitary 2011-06, Vol.14 (2), p.148-156
Hauptverfasser:	Vilar, Lucio, Azevedo, Monalisa F., Naves, Luciana Ansaneli, Casulari, Luiz Augusto, Albuquerque, José Luciano, Montenegro, Renan M., Figueiredo, Patricia, Nascimento, Gilvan C., Faria, Manuel S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acromegaly - drug therapy Acromegaly - etiology Adenoma - complications Adenoma - drug therapy Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Delayed-Action Preparations - administration & dosage Drug Resistance, Neoplasm - drug effects Endocrinology Ergolines - administration & dosage Ergolines - pharmacology Female Growth Hormone-Secreting Pituitary Adenoma - complications Growth Hormone-Secreting Pituitary Adenoma - drug therapy Human Physiology Humans Insulin-Like Growth Factor I - administration & dosage Insulin-Like Growth Factor I - therapeutic use Male Medicine Medicine & Public Health Middle Aged Octreotide - administration & dosage Time Factors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!